Patients transitioning from injectable obesity medications to Novo Nordisk’s new Wegovy pill continue to shed weight, according to fresh real world data presented this week. The analysis suggests that moving to a tablet doesn’t just help patients maintain the progress they made on shots but may actually accelerate further weight loss. This finding offers a glimmer of hope for those weary of weekly needles, suggesting that long term weight management could eventually move away from subcutaneous injections toward more convenient daily pills.
The study utilized data from the Ro telehealth platform, tracking nearly 200 patients who had previously used either Novo’s Wegovy injection or Eli Lilly’s Zepbound. On average, those who switched to the oral version lost an additional 8.8 pounds over three months, representing roughly a 4 percent drop in total body weight. Beyond the scale, the impact was visible in lifestyle improvements, with many participants reporting that their clothes fit better and that they felt motivated to pursue healthier eating habits. About 75 percent of these patients expressed satisfaction with the switch, citing ease of use and the lack of need for refrigeration during travel.
Martin Holst Lange, Novo’s chief scientific officer, noted that while clinicians once assumed most patients were content with injections, there is now a clear and growing preference for oral treatments. He emphasized that the pill maintains a similar safety and tolerability profile to the injection while potentially offering slightly better results. However, the company cautioned that because this was a real world study relying on self reported telehealth data, the results might not be perfectly generalizable to every single patient across the broader population.
While focusing on current options, Novo also teased future breakthroughs with its next generation drug, CagriSema. New imaging research indicates this upcoming medication can reduce food noise by changing how the brain reacts to high calorie temptations. Preliminary findings suggest CagriSema may go beyond simple weight loss by improving organ health—specifically reducing fat around the liver and pancreas—and maintaining bone density even as users lose significant weight. These combined advancements signal a shift toward treating obesity as a complex systemic condition involving both brain chemistry and multi organ health.
